A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt".

S.J. Res. 141, introduced by Sen. Warnock (D-GA) on March 19, 2026, is a Congressional Review Act joint resolution disapproving the CFPB's withdrawal of the 'Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt' rule. The effect would be to reinstate the stricter 2024 rule, which requires debt collectors to verify medical debt more thoroughly, restricts communication practices, and limits reporting to credit bureaus. The bill was discharged from the Senate Banking Committee on April 27, 2026, and placed on the Senate Legislative Calendar (Calendar No. 393). It has NOT passed — it is at the floor consideration stage in the Senate. No House companion bill has been introduced. This bill authorizes zero funding — it is a regulatory disapproval, not a spending bill. The mechanism is purely regulatory: it blocks the CFPB's 2025 deregulatory action and brings back the 2024 rule as if the withdrawal never occurred. The money trail flows through reduced collection revenue for debt collectors (both third-party agencies and healthcare provider-owned collection operations) and increased bad debt for hospitals, clinics, and physician practices. Structural winners: Healthcare insurers like UnitedHealth Group could see a minor benefit if stricter collection reduces provider willingness to serve high-balance patients, potentially shifting more patients to insurance-covered settings. Credit bureaus (e.g., Fair Isaac Corporation, $FICO) face reduced medical debt credit reporting, which may lower the predictive value of credit scores for a segment of consumers, but the revenue impact is negligible given $FICO's diverse scoring portfolio. Structural losers: Healthcare providers with high patient out-of-pocket exposure are most affected. Encompass Health ($EHC), which operates post-acute rehabilitation hospitals with significant Medicare deductible/co-insurance exposure, faces increased bad debt. Debt collection agencies and specialized receivables management firms (e.g., privately held companies like Revenue Enterprises or within larger financial services) face direct compliance cost increases. Pure-play debt collection firms are not publicly traded in the US, limiting ticker impact. Real market data analysis: $EHC is down 0.47% in the 7 days ending April 28 (from $102.17 to $101.69), while the S&P 500 was roughly flat. The 30-day change is +4.22%, reflecting broader sector recovery. is up 3.75% in the 7 days and +41.6% in 30 days, driven by earnings momentum and regulatory clarity — the medical debt rule has not been a headline risk for UNH relative to other factors. $FICO is up 4.16% over 7 days but flat over 30 days (-0.06%), consistent with its algorithmic pricing model being unaffected by medical debt credit reporting changes. Timeline: The resolution is on the Senate Legislative Calendar and can be brought to the floor at any time. With a Democratic sponsor and the Senate controlled by Democrats (119th Congress), passage is possible but requires 50 votes and VP tiebreaker. The House has not acted. If it passes both chambers, it faces a presidential signature — it is unclear whether the White House would sign a CRA resolution affecting a regulation the administration itself withdrew. The 60-day CRA window for the May 2025 rule may already have expired, creating procedural questions.